• URB597 (KDS-4103): Precision FAAH Inhibition in Pain Researc

  2026-06-22

  URB597 (KDS-4103) sets the benchmark for selective FAAH inhibition, enabling researchers to dissect endocannabinoid signaling with high specificity. Discover practical protocols, troubleshooting tips, and insights from new pain models that maximize the value of URB597 in translational neuroplasticity and inflammation research.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor In

  2026-06-21

  Wang et al. (2018) systematically dissected the entry mechanism of genotype III grass carp reovirus (GCRV104), revealing clathrin-mediated endocytosis as the primary cellular uptake route. Their inhibitor analysis—highlighting the lack of effect from actin polymerization inhibitors—refines understanding of aquatic reovirus infection and informs experimental design in cytoskeletal research.

• AMG 487 and the CXCL10-CXCR3 Axis: New Frontiers in Macropha

  2026-06-20

  Explore how AMG 487, a potent CXCR3 antagonist, enables state-specific control of macrophage polarization and inflammation. This article uniquely dissects the context-dependent actions of AMG 487 and their implications for advanced assay design.

• SU 5402 in Human Neuronal Models: Expanding Beyond Oncology

  2026-06-19

  Explore SU 5402's role in advanced human sensory neuron research, extending its utility beyond cancer biology. This article reveals unique assay strategies using SU 5402, with insights grounded in the latest scientific advances.

• Vorinostat (SAHA): Strategic Epigenetic Modulation in Oncolo

  2026-06-19

  This thought-leadership article explores how Vorinostat (suberoylanilide hydroxamic acid) enables translational researchers to bridge mechanistic epigenetic modulation with actionable strategies in cancer biology. By integrating recent comparative evidence—such as the superior in vivo activity of M344 in neuroblastoma models—with practical guidance for protocol design, this commentary positions Vorinostat not just as a classic HDAC inhibitor, but as a flexible, benchmark agent for apoptosis induction and translational oncology workflows. The article also highlights clinical and experimental nuances, future research opportunities, and how APExBIO’s Vorinostat offers workflow-ready reliability for advanced studies.

• Sunitinib in RCC: Mechanisms, Resistance, and Translational

  2026-06-18

  A deep dive into the mechanistic action of Sunitinib as a multi-targeted receptor tyrosine kinase inhibitor in renal cell carcinoma, with a strategic perspective on overcoming resistance and guiding translational research.

• Applied Workflows with Recombinant Human EGF: Spheroid Assay

  2026-06-18

  Harnessing recombinant human EGF unlocks advanced, reproducible control over cell proliferation and stemness detection in glioblastoma and regenerative models. This guide translates cutting-edge protocol innovations and troubleshooting strategies into direct experimental advantages, leveraging APExBIO’s high-purity EGF for superior assay performance.

• Bleomycin Sulfate: Mechanistic Insight and Strategic Leverag

  2026-06-17

  Explore how Bleomycin Sulfate (Blenoxane) enables advanced translational research by bridging mechanistic understanding of DNA damage and fibrosis with actionable protocol guidance. This article unpacks recent breakthroughs in mitophagy, highlights APExBIO's product strengths, and delivers a forward-looking perspective for researchers tackling pulmonary fibrosis and oncology models.

• Fluorescein Tyramide in Circuit Mapping: Signal Amplificatio

  2026-06-17

  Explore how Fluorescein Tyramide enables ultra-sensitive neural circuit mapping by achieving robust signal amplification in immunohistochemistry and in situ hybridization. This in-depth article reveals scientific insights, advanced protocols, and practical assay recommendations distinct from prior content.

• Pentoxifylline Modulates Hyperinflammation in Preterm Monocy

  2026-06-16

  This study demonstrates that pentoxifylline (PTX) significantly downregulates LPS-induced inflammatory responses in preterm infant monocytes by targeting TLR4 signaling and cytokine expression. The findings provide mechanistic insight into PTX’s age-dependent immunomodulatory effects and support its ongoing evaluation in neonatal sepsis models.

• Structural Insights into HCAR3 Agonist Recognition and Selec

  2026-06-16

  This study presents high-resolution cryo-EM structures of the hydroxycarboxylic acid receptor 3 (HCAR3) in complex with selective agonists, including Acifran, revealing the molecular determinants of ligand recognition and selectivity. These findings advance our understanding of GPCR-mediated lipid metabolism regulation and inform the rational design of HCAR3-specific hypolipidemic agents.

• Buffer Optimization Stabilizes RNA LNPs for Nebulized Lung D

  2026-06-15

  This study demonstrates that optimizing nebulization buffer composition can significantly stabilize RNA-loaded lipid nanoparticles (LNPs) for inhalable delivery. By fine-tuning buffer pH and excipient selection, the approach preserves nanoparticle size, RNA encapsulation, and bioactivity, addressing a core challenge in pulmonary RNA therapeutics.

• ICG001: Wnt/β-Catenin Pathway Inhibitor in Translational Res

  2026-06-15

  ICG001 empowers researchers to dissect Wnt/β-catenin signaling with precision, enabling advanced modeling of cancer and fibrosis. This comprehensive guide outlines practical workflows, troubleshooting insights, and recent innovation, making ICG001 an essential tool for translational science.

• CDC42 Polarity Regulates Intestinal Stem Cell Fate via YAP-m

  2026-06-14

  Zhang et al. uncover how CDC42-driven epithelial polarity orchestrates the balance between intestinal stem cells and transit amplifying cells through YAP-EGF-mTOR signaling, independently of Wnt pathways. These findings provide a mechanistic basis for epithelial homeostasis and open new avenues for gastrointestinal stem cell research.

• Antiarrhythmic Drugs and KCa2 Channel Modulation in AF Resea

  2026-06-13

  This study systematically evaluates whether established antiarrhythmic agents, including Dronedarone (Multaq), directly inhibit small conductance calcium-activated potassium (KCa2) channels at concentrations relevant for atrial fibrillation (AF) treatment. Findings indicate that most clinically used drugs lack meaningful KCa2 channel inhibition, highlighting the need for new atrial-selective pharmacological strategies.

15453 records 3/1031 page Previous Next 12345 下5页 Last page